Akebia Therapeutics (AKBA) has released an update to notify the public and investors about a termination of a material definitive agreement.
On November 11, 2019, the Company settled its obligations under a previous loan agreement with Pharmakon by entering into a new Credit Agreement. The original loan and related documents were terminated, the Company’s debts were paid in full, and Pharmakon’s security interests in the Company’s assets were released.
For further insights into AKBA stock, check out TipRanks’ Stock Analysis page.
For a comprehensive understanding of the announcement, you can read the full document here.
